New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

References

• Sawyers C L. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340
   PubMed Web of Science ®Google Scholar
• Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 2007; 48: 2310–2322
   PubMed Web of Science ®Google Scholar
• Khorashad J S, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 658–663
   PubMed Web of Science ®Google Scholar
• Branford S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283
   PubMed Web of Science ®Google Scholar
• Soverini S, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100–4109
   PubMed Web of Science ®Google Scholar
• Pfeifer H, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727–734
   PubMed Web of Science ®Google Scholar
• Kimura S. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. Recent Patents Anticancer Drug Discov 2006; 1: 347–355
   PubMed Web of Science ®Google Scholar
• Soverini S, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 2004; 50: 1205–1213
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide C A, Deininger M W. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008; 17: 865–878
   PubMed Web of Science ®Google Scholar
• Nicolini F E, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061–1066
   PubMed Web of Science ®Google Scholar
• Ernst T, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008; 93: 186–192
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide C A, Deininger M W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242–2249
   PubMed Web of Science ®Google Scholar
• Deininger M W, et al. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 2004; 18: 864–871
   PubMed Web of Science ®Google Scholar
• Shah N P, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125
   PubMed Web of Science ®Google Scholar
• Gorre M E, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne C, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018
   PubMed Web of Science ®Google Scholar
• Baccarani M, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809–1820
   PubMed Web of Science ®Google Scholar
• Hochhaus A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196
   PubMed Web of Science ®Google Scholar
• Soverini S, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007; 92: 401–404
   PubMed Web of Science ®Google Scholar
• Shah N P, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562–2569
   PubMed Web of Science ®Google Scholar
• Irving J AE, et al. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clin Chem 2004; 50: 1233–1237
   PubMed Web of Science ®Google Scholar
• Chomel J C, et al. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leuk Res 2009; 33: 551–555
   PubMed Web of Science ®Google Scholar
• Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008; 1: 15
   PubMed Web of Science ®Google Scholar
• Ernst T, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008; 93: 1389–1393
   PubMed Web of Science ®Google Scholar
• Wolford J K, et al. High-throughput SNP detection by using DNA pooling and denaturing high performance liquid chromatography (DHPLC). Hum Genet 2000; 107: 483–487
   PubMed Web of Science ®Google Scholar
• Baumer A, et al. A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum Mutat 2001; 17: 423–430
   PubMed Web of Science ®Google Scholar
• Emmerson P, et al. Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat 2003; 21: 112–115
   PubMed Web of Science ®Google Scholar
• Chien J H, et al. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res 2008; 32: 1724–1734
   PubMed Web of Science ®Google Scholar